Investigating the Potential Impact of LH on the Progression of Alzheimer’s Disease via Microglia Activation and C/EBPβ pathway
DOI:
https://doi.org/10.61173/99782h90Keywords:
Alzheimer's disease, luteinizing hormone, microglial function, C/EBPβ, AEP/δ-secretaseAbstract
Background: Alzheimer’s disease (AD) is a neurodegenerative disease that causes irreversible cognitive decline and memory loss. The disproportionate effect of AD on postmenopausal women prompts investigation into the role of hormonal changes in disease pathogenesis. However, previous studies on estrogen replacement therapies have shown inconsistent results. Therefore, further confirmation is needed to ensure the independent effects of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) on AD pathology. Our study will 1) focus on microglial activation pathway 2) focus on the LH-C/EBPβ-AEP pathway and its potential influence on AD progression.Methods: Using cell lines to investigate whether microglial activation is present. HMC3 cells will be treated with LH or control phosphate buffered saline (PBS). Carry out Western Blot (WB) and qPCR to confirm presence of cytokines, which is the product of microglial activation. Using 3xTg-AD mice treated with LH or control PBS. To identify AD progression, immunofluorescent (IF) micrograph will be used to quantify amyloid-beta (Aβ) load. WB and qPCR will be used to identify cytokines. Morris water maze (MWM) will be carried out for cognitive testing. Using an ovariectomized mice model to investigate the LH-C/EBPβ-AEP pathway. Mice will be treated with LH antibodies or control IgG, followed by assessments using IVIS imaging and MWM test to measure spatial memory. IF, WB and qPCR will be used to quantify Aβ and Tau protein levels and gene expression changes. Furthermore, the study will explore the precise relationship between LH and C/EBPβ expression through inhibition experiments targeting AKT and ERK1/2 signaling pathways.Expected results: Our hypothesis is that LH activates microglia, with both pro-inflammatory and anti-inflammatory cytokine released. This change in microglia function suggests LH has an effect on microglia and hence removal of Aβ plaques. Another hypothesis is that LH antibody manages to cross the blood-brain barrier. The cognitive ability will be improved in LH-Ab treated mice with reduced Aβ and Tau protein levels and downregulation of the C/EBPβ–AEP/δ-secretase pathway. Simultaneously, we expect that there will be a positive correlation between LH levels and expression of C/EBPβ-related pathways, suggesting the involvement of AKT and ERK1/2 signaling pathways in AD progression.Conclusion: This study aims to provide evidence for the link between LH activation of the C/EBPβ pathway and AEP production, promoting our understanding of AD pathogenesis. The insights gained may implicate therapeutic strategies targeting LH mechanisms in postmenopausal women at risk of AD.
References
[1] Ambrose, C.T. (2013). Alzheimer’s Disease: The Great Morbidity of the 21st Century. American Scientist, [online] 101(3), pp.194–201. Available at: https://www.jstor.org/ stable/43707701 [Accessed 14 Jul. 2024].
[2] Sliwinski, J.R., Johnson, A.K. and Elkins, G.R. (2014). Memory Decline in Peri- and Post-menopausal Women: The Potential of Mind–Body Medicine to Improve Cognitive Performance. Integrative Medicine Insights, 9, p.IMI.S15682. doi:https://doi.org/10.4137/imi.s15682.
[3] Motlani, V., Motlani, G., Pamnani, S., Sahu, A. and Acharya, N. (2023). Changed Endocrinology in Postmenopausal Women: A Comprehensive View. Cureus, [online] 15(12). doi:https://doi.org/10.7759/cureus.51287.
[4] Marques, P., Skorupskaite, K., George, J.T. and Anderson, R.A. (2018). Physiology of GNRH and Gonadotropin Secretion. [online] Nih.gov. Available at: https://www.ncbi.nlm.nih.gov/ books/NBK279070/.
[5] Shumaker, S.A. (2004). Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal WomenWomen’s Health Initiative Memory Study. JAMA, 291(24), p.2947. doi:https://doi.org/10.1001/ jama.291.24.2947.
[6] Henderson, V.W., Benke, K.S., Green, R.C., Cupples, L.A. and Farrer, L.A. (2005). Postmenopausal hormone therapy and Alzheimer’s disease risk: interaction with age. Journal of Neurology, Neurosurgery & Psychiatry, [online] 76(1), pp.103– 105. doi:https://doi.org/10.1136/jnnp.2003.024927.
[7] Xiong, J., Kang, S.S., Wang, Z., Liu, X., Kuo, T.-C., Korkmaz, F., Padilla, A., Miyashita, S., Chan, P., Zhang, Z., Katsel, P., Burgess, J., Gumerova, A., Ievleva, K., Sant, D., Yu, S.-P., Muradova, V., Frolinger, T., Lizneva, D. and Iqbal, J. (2022). FSH blockade improves cognition in mice with Alzheimer’s disease. Nature. doi:https://doi.org/10.1038/s41586- 022-04463-0.
[8] Xiong, J., Kang, S.S., Wang, M., Wang, Z., Xia, Y., Liao, J., Liu, X., Yu, S.-P., Zhang, Z., Ryu, V., Yuen, T., Zaidi, M. and Ye, K. (2023). FSH and ApoE4 contribute to Alzheimer’s diseaselike pathogenesis via C/EBPβ/δ-secretase in female mice. Nature Communications, [online] 14(1), p.6577. doi:https://doi. org/10.1038/s41467-023-42282-7.
[9] Zhang, Y.-N., Chen, X.-L., Guo, L.-Y., Jiang, P.-R., Lu, H., Pan, K., Guo, L., Hu, Y.-T. and Bao, A.-M. (2024). Downregulation of peripheral luteinizing hormone rescues ovariectomy-associated cognitive deficits in APP/PS1 mice. Neurobiology of Aging, [online] 135, pp.60–69. doi:https://doi. org/10.1016/j.neurobiolaging.2023.12.007.
[10] Casadesus, G., Webber, K.M., Atwood, C.S., Pappolla, M.A., Perry, G., Bowen, R.L. and Smith, M.A. (2006). Luteinizing hormone modulates cognition and amyloid-β deposition in Alzheimer APP transgenic mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1762(4), pp.447–452. doi:https://doi.org/10.1016/j.bbadis.2006.01.008.
[11] Colonna M., Butovsky O. (2017). Microglia Function in the Central Nervous System During Health and Neurodegeneration. Annu. Rev. 35441–468. 10.1146/annurevimmunol-051116-052358
[12] Antonín Bukovský, Korakod Indrapichate, Fujiwara, H., Cekanova, M., Marı́a Elena Ayala, Domı́nguezR., Caudle, M.R., Wimalsena, J., Elder, R.F., Copas, P., Foster, J.S., Fernando, R.I., Henley, D.C. and Upadhyaya, N.B. (2003). Multiple luteinizing hormone receptor (LHR) protein variants, interspecies reactivity of anti-LHR mAb clone 3B5, subcellular localization of LHR in human placenta, pelvic floor and brain, and possible role for LHR in the development of abnormal pregnancy, pelvic floor disorders and Alzheimer’s disease. Reproductive Biology and Endocrinology, 1(1), pp.46–46. doi:https://doi. org/10.1186/1477-7827-1-46.
[13] Wang, Z.-H., Gong, K., Liu, X., Zhang, Z., Sun, X., Wei, Z.Z., Yu, S.P., Manfredsson, F.P., Sandoval, I.M., Johnson, P.F., Jia, J., Wang, J.-Z. and Ye, K. (2018). C/EBPβ regulates delta- Dean&Francis secretase expression and mediates pathogenesis in mouse models of Alzheimer’s disease. Nature Communications, 9(1). doi:https://doi.org/10.1038/s41467-018-04120-z.
[14] Jafari, A., Qanie, M., Thomas Levin Andersen, Zhang, Y., Chen, L., Benno Postert, Parsons, S., Ditzel, N., Khosla, S., Harald Thidemann Johansen, Per Kjærsgaard‐Andersen, Jean‐ Marie Delaissé, Abdallah, B.M., Hesselson, D., Solberg, R. and Kassem, M. (2017). Legumain Regulates Differentiation Fate of Human Bone Marrow Stromal Cells and Is Altered in Postmenopausal Osteoporosis. Stem Cell Reports, 8(2), pp.373– 386. doi:https://doi.org/10.1016/j.stemcr.2017.01.003.
[15] Yao, Q., Long, C., Yi, P., Zhang, G., Wan, W., Rao, X., Ying, J., Liang, W. and Hua, F. (2024). C/EBPβ: A transcription factor associated with the irreversible progression of Alzheimer’s disease. CNS neuroscience & therapeutics, 30(4). doi:https:// doi.org/10.1111/cns.14721.
[16] Zhang, Z., Tian, Y. and Ye, K. (2020). δ-secretase in neurodegenerative diseases: mechanisms, regulators and therapeutic opportunities. Translational Neurodegeneration, 9(1). doi:https://doi.org/10.1186/s40035-019-0179-3.
[17] Behrendt, A., Bichmann, M., Ercan-Herbst, E., Haberkant, P., Schöndorf, D.C., Wolf, M., Fahim, S.A., Murolo, E. and Ehrnhoefer, D.E. (2019). Asparagine endopeptidase cleaves tau at N167 after uptake into microglia. Neurobiology of Disease, [online] 130, p.104518. doi:https://doi.org/10.1016/ j.nbd.2019.104518.
[18] Karlsson, A., Maizels, E.T., Flynn, M.P., Jones, J., Shelden, E.A., Bamburg, J.R. and Hunzicker-Dunn, M. (2010). Luteinizing Hormone Receptor-Stimulated Progesterone Production by Preovulatory Granulosa Cells Requires Protein Kinase A-Dependent Activation/Dephosphorylation of the Actin Dynamizing Protein Cofilin. Molecular Endocrinology, 24(9), pp.1765–1781. doi:https://doi.org/10.1210/me.2009-0487.
[19] Pulido-Salgado, M., Vidal-Taboada, J.M. and Saura, J. (2015). C/EBPβ and C/EBPδ transcription factors: Basic biology and roles in the CNS. Progress in Neurobiology, [online] 132, pp.1–33. doi:https://doi.org/10.1016/j.pneurobio.2015.06.003.
[20] Reactome.org. (n.d.). Reactome | MAPK3 (ERK1) and MAPK1 (ERK2) phosphorylate CEBPB. [online] Available at: https://reactome.org/content/detail/R-HSA-3857329.
[21] Dello Russo, C., Cappoli, N., Coletta, I., Mezzogori, D., Paciello, F., Pozzoli, G., Navarra, P. and Battaglia, A. (2018b). The human microglial HMC3 cell line: where do we stand? A systematic literature review. Journal of Neuroinflammation, 15(1). doi:https://doi.org/10.1186/s12974-018-1288-0
[22] Ramberg, V., Tracy, L.M., Samuelsson, M., Nilsson, L.N. and Iverfeldt, K. (2011). The CCAAT/enhancer binding protein (C/EBP) δ is differently regulated by fibrillar and oligomeric forms of the Alzheimer amyloid-β peptide. Journal of Neuroinflammation, 8(1). doi:https://doi.org/10.1186/1742- 2094-8-34.
[23] C/EBPβ/AEP is age-dependently activated in Parkinson’s disease and mediates α-synuclein in the gut and brain. ProQuest, [online] p.1. doi:https://doi.org/10.1038/s41531-022-00430-8.
[24] Xiong, J., Kang, S.S., Wang, M., Wang, Z., Xia, Y., Liao, J., Liu, X., Yu, S.-P., Zhang, Z., Ryu, V., Yuen, T., Zaidi, M. and Ye, K. (2023). FSH and ApoE4 contribute to Alzheimer’s diseaselike pathogenesis via C/EBPβ/δ-secretase in female mice. Nature Communications, [online] 14(1), p.6577. doi:https://doi. org/10.1038/s41467-023-42282-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
